Presentation is loading. Please wait.

Presentation is loading. Please wait.

Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial by Dieter Hoelzer,

Published byMonica Chandler Modified over 8 years ago

Similar presentations

Presentation on theme: "Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial by Dieter Hoelzer,"— Presentation transcript:

1 Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial by Dieter Hoelzer, Jan Walewski, Hartmut Döhner, Andreas Viardot, Wolfgang Hiddemann, Karsten Spiekermann, Hubert Serve, Ulrich Dührsen, Andreas Hüttmann, Eckhard Thiel, Jolanta Dengler, Michael Kneba, Markus Schaich, Ingo G. H. Schmidt-Wolf, Joachim Beck, Bernd Hertenstein, Albrecht Reichle, Katarzyna Domanska-Czyz, Rainer Fietkau, Heinz-August Horst, Harald Rieder, Stefan Schwartz, Thomas Burmeister, and Nicola Gökbuget Blood Volume 124(26):3870-3879 December 18, 2014 ©2014 by American Society of Hematology

2 Consort diagram depicting enrollment, exclusion, and treatment realization. Dieter Hoelzer et al. Blood 2014;124:3870-3879 ©2014 by American Society of Hematology

3 Treatment scheme and the detailed treatment application for patients aged 15 to 55 years. Dieter Hoelzer et al. Blood 2014;124:3870-3879 ©2014 by American Society of Hematology

4 A+B 5-year probability of OS and PFS in Burkitt lymphoma/leukemia patients. Dieter Hoelzer et al. Blood 2014;124:3870-3879 ©2014 by American Society of Hematology

5 Five-year probability of OS in Burkitt lymphoma/leukemia patients according to risk factors. Dieter Hoelzer et al. Blood 2014;124:3870-3879 ©2014 by American Society of Hematology

Download ppt "Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial by Dieter Hoelzer,"

Similar presentations

Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD by Attilio.

Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD by Attilio.
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial by Stephan Stilgenbauer, Andrea Schnaiter, Peter Paschka,

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial by Stephan Stilgenbauer, Andrea Schnaiter, Peter Paschka,
A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without.

A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without.
Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome by Bart.

Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome by Bart.
Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia by Natali Pflug, Jasmin Bahlo, Tait D. Shanafelt, Barbara.

Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia by Natali Pflug, Jasmin Bahlo, Tait D. Shanafelt, Barbara.
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.
Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large.

Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large.
High Cure Rates of the Short-Term GITIL Chemotherapy Programme for Adult Patients with Burkitt Lymphoma by Jacopo Mariotti, Anna Guidetti, Michele Magni,

High Cure Rates of the Short-Term GITIL Chemotherapy Programme for Adult Patients with Burkitt Lymphoma by Jacopo Mariotti, Anna Guidetti, Michele Magni,
Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia by Klaus H. Metzeler, Tobias Herold, Maja Rothenberg-Thurley, Susanne.

Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia by Klaus H. Metzeler, Tobias Herold, Maja Rothenberg-Thurley, Susanne.
Diffuse Large B-Cell Lymphoma (DLBCL) Patients Failing Second-Line R-DHAP Or R-ICE Chemotherapy Included In The Coral Study by Eric Van Den Neste, Christian.

Diffuse Large B-Cell Lymphoma (DLBCL) Patients Failing Second-Line R-DHAP Or R-ICE Chemotherapy Included In The Coral Study by Eric Van Den Neste, Christian.
by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E

by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E
Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,

Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,
Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy.

Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy.
A Prospective Randomized Trial of Buffy Coat Versus CD34-Selected Autologous Bone Marrow Support in High-Risk Breast Cancer Patients Receiving High-Dose.

A Prospective Randomized Trial of Buffy Coat Versus CD34-Selected Autologous Bone Marrow Support in High-Risk Breast Cancer Patients Receiving High-Dose.
Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic.

Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic.
A Randomized Trial Of Daily Prednisone Versus Pulsed Dexamethasone In Treatment Naïve Patients With Idiopathic Thrombocytopenic Purpura by Johannes Matschke,

A Randomized Trial Of Daily Prednisone Versus Pulsed Dexamethasone In Treatment Naïve Patients With Idiopathic Thrombocytopenic Purpura by Johannes Matschke,
Improved outcome in central nervous system aspergillosis, using voriconazole treatment by Stefan Schwartz, Markus Ruhnke, Patricia Ribaud, Lawrence Corey,

Improved outcome in central nervous system aspergillosis, using voriconazole treatment by Stefan Schwartz, Markus Ruhnke, Patricia Ribaud, Lawrence Corey,
Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV.

Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV.
Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy by Georg.

Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy by Georg.
Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model by Tobias Tritschler, Marie.

Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model by Tobias Tritschler, Marie.

Similar presentations

Ads by Google